Karuna Therapeutics, Inc. focused on targeting muscarinic receptors for the treatment of neuropsychiatric disorders, including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain, has raised an additional $12 million of funding as an extension of its Series B financing previously announced in March 2019.
April 1, 2019
· 4 min read